Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 801–900 of 1,000
Manzano, J. L., Martín-Liberal, J., Fernandez-Morales, L. A., Benítez, G., Martínez, J. M., Quindós, M., García‐Castaño, A., Fernández, O., Simó, R. V., Majem, M., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000888 · Cited by 13
Amaral, T. M. S., Nanz, L., Stadler, R., Berking, C., Ulmer, A., Forschner, A., Meiwes, A., Wolfsperger, F., Meraz-Torres, F., Chatziioannou, E., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113912 · Cited by 14
Bührer, E., Kiciński, M., Mandalà, M., Pe, M. L., Long, G. V., Atkinson, V. G., Blank, C. U., Haydon, A. M., Dalle, S., Khattak, A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00338-3 · Cited by 16
Self-citationSong, Y., Tieniber, A. D., Gimotty, P. A., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., Fraker, D. L., & Karakousis, G. C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07599-y · Cited by 14
Eggermont, A. M. M., Rutkowski, P. L., Dutriaux, C., Hofman‐Wellenhof, R., Dziewulski, P. G., Marples, M., Grange, F., Lok, C., Pennacchioli, E., Robert, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.015 · Cited by 14
Self-citationAdjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma
Bruce, W. J., Koljonen, J. L., Romanelli, M. R., Khan, A. U., & Neumeister, M. W. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.001 · Cited by 13
van Laar, S. A., Kapiteijn, E., Handoko, K. B., Guchelaar, H., & Zwaveling, J. (2022) · Cancers · doi:10.3390/cancers14215426 · Cited by 15
“Besides, manifestations of thyroiditis, hyperthyroidism (N: 15%, P: 13%) and hypothyroidism (N: 20%, P: 19%) seemed to occur more often in this study than in the trials (hyperthyroidism, N: 8%, P: 10%; hypothyroidism: N: 10%, 14%) [8,12].”
BackgroundResultInfluentialTeras, J., Kroon, H. M., Miura, J. T., Kenyon-Smith, T., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M., Farley, C. R., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08312-0 · Cited by 14
Dummer, R., Guo, J., Luke, J. J., Carlino, M. S., Schadendorf, D., Khattak, M. A., Hauschild, A., Ascierto, P. A., Chen, Y., Shin, S. J., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00709-0 · Cited by 13
Self-citationSchildbach, V. A. S., Horn, S., Hidalgo-Gadea, G., Johannis, W., Mauch, C., & Franklin, C. (2023) · Cancers · doi:10.3390/cancers15030702 · Cited by 13
“Still, a large number of patients do not benefit from adjuvant therapy, either because of primary or secondary resistance to adjuvant treatment or because they would not have developed metastases even without adjuvant treatment [6,7].”
BackgroundShah, P., Trepanowski, N., Grant-Kels, J. M., & LeBoeuf, M. R. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.05.024 · Cited by 13
Lorenzi, M. F., Arndorfer, S., Aguiar‐Ibáñez, R., Scherrer, E., Liu, F. X., & Krepler, C. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1649266 · Cited by 13
“KEYNOTE 054 III Double-blind Yes 18 III ECOG 0-1 NCT02362594 Eggermont et al.(11) — Lian 2013 II — No 18 II–III ECOG 0-1 ChiCTR-TRC-11001798 Lian et al.”
BackgroundElderly Age Is Associated With More Conservative Treatment of Invasive Melanoma
Bateni, S. B., Johns, A. J., Gingrich, A. A., Gholami, S., Bold, R. J., Canter, R. J., & Kirane, A. (2020) · Anticancer Research · doi:10.21873/anticanres.14266 · Cited by 13
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era
Straker, R. J., Song, Y., Sun, J. X., Shannon, A. B., Cohen, L. S., Muradova, E., Daou, H., Krause, K., Li, S., Frederick, D. T., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09384-8 · Cited by 13
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
Livingstone, A., Dempsey, K., Stockler, M. R., Howard, K., Long, G. V., Carlino, M. S., Menzies, A. M., & Morton, R. L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08752-1 · Cited by 14
Self-citationEmerging Therapies in the Treatment of Advanced Melanoma
Massand, S., & Neves, R. I. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.008 · Cited by 14
Functionalization of Nanomaterials for Skin Cancer Theranostics
Zhang, C., Zhu, X., Hou, S., Pan, W., & Liao, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.887548 · Cited by 14
Uchida, Y., Kinose, D., Nagatani, Y., Tanaka‐Mizuno, S., Nakagawa, H., Fukunaga, K., Yamaguchi, M., & Nakano, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09642-w · Cited by 15
Is Melanoma Progression Affected by Thyroid Diseases?
Ulisse, S., Baldini, E., Pironi, D., Gagliardi, F., Tripodi, D., Lauro, A., Carbotta, S., Tarroni, D., D’Armiento, M., Morrone, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710036 · Cited by 14
Castle, J. T., Adatorwovor, R., Levy, B. E., Marcinkowski, E., Merritt, A. S., Stapleton, J. L., & Burke, E. E. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12745-0 · Cited by 13
Current Controversies in Melanoma Treatment
Temple‐Oberle, C. F., Nicholas, C., & Rojas-García, P. (2023) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009936 · Cited by 13
Ugurel, S., & Gutzmer, R. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15053_g · Cited by 13
Self-citationZaremba, A., Mohr, P., Gutzmer, R., Meier, F. E., Pföhler, C., Weichenthal, M., Terheyden, P. A. M., Forschner, A., Leiter, U., Ulrich, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.008 · Cited by 13
Self-citationPlaczke, J., Rosińska, M., Sobczuk, P., Ziętek, M., Kempa-Kamińska, N., Cybulska-Stopa, B., Kamińska‐Winciorek, G., Bal, W., Mackiewicz, J., Galus, Ł., et al. (2023) · Cancers · doi:10.3390/cancers15174384 · Cited by 14
Self-citationEmerging prognostic biomarkers in advanced cutaneous melanoma: a literature update
Roccuzzo, G., Bongiovanni, E., Tonella, L., Pala, V., Marchisio, S., Ricci, A., Senetta, R., Bertero, L., Ribero, S., Berrino, E., et al. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2314574 · Cited by 13
“…the BRAF-MEK pathway or with immune checkpoint inhibitors (ICI) have represented a breakthrough enabling clinically meaningful improvements in overall survival (OS), relapse-free-survival (RFS) and progression-free-survival (PFS) in both adjuvant and metastatic settings, respectively [4–7].”
BackgroundStadler, R., Leiter, U., & Garbe, C. (2018) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13707 · Cited by 13
Song, Y., Shannon, A. B., Fraker, D. L., & Karakousis, G. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25600 · Cited by 13
Sharma, R., Koruth, R., Kanters, S., Druyts, E., & Tarhini, A. A. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0061 · Cited by 13
An overview of binimetinib for the treatment of melanoma
Specenier, P. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729122 · Cited by 13
Kır, G., Tarcan, Z. C., Söylemez, T., Aydin, A., Demircan, B., Kaya, I. A., & McCluggage, W. G. (2020) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000750 · Cited by 14
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
Boulva, K., Apte, S. S., Yu, A. M., Tran, A., Shorr, R., Song, X., Ong, M., & Nessim, C. (2021) · Cancers · doi:10.3390/cancers13081905 · Cited by 14
“74]) [16], while NIVO versus IPI showed improved 4-year RFS (HR 0.”
BackgroundSharouni, M. E., Laeijendecker, A. E., Suijkerbuijk, K. P. M., Witkamp, A. J., Sigurdsson, V., van Diest, P. J., van Gils, C. H., & Blokx, W. A. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.001 · Cited by 13
Current management of melanoma patients with nodal metastases
Han, D., van Akkooi, A. C. J., Straker, R. J., Shannon, A. B., Karakousis, G. C., Wang, L., Kim, K. B., & Reintgen, D. S. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10099-7 · Cited by 14
“Recent follow-up data for the EORTC 1325/Keynote 054 study demonstrated a continuing RFS advantage for pembrolizumab [51].”
BackgroundMethodRe, M. D., Vivaldi, C., Rofi, E., Salani, F., Crucitta, S., Catanese, S., Fontanelli, L., Massa, V., Cucchiara, F., Fornaro, L., et al. (2021) · Cancers · doi:10.3390/cancers13153738 · Cited by 13
“Recently, inhibition of the PD-1/PD-L1 axis by immune checkpoint inhibitors (ICIs) has substantially changed the therapeutic landscape of several malignancies, including melanoma [9], non-small cell lung cancer [10,11], urothelial carcinoma [12], and renal cancer [13].”
BackgroundFox, J. A., Langbecker, D., Rosenberg, J. P., & Ekberg, S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17511 · Cited by 13
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
Kim, H. Y., Upadhyay, P. J., Fahmy, A., Liu, X., Duong, J. K., & Boddy, A. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00753-5 · Cited by 14
Efficacy of Immune Checkpoint Inhibitors in Cancer Patients of Different Ages: A Meta-Analysis
Li, J., & Gu, J. H. (2019) · Future Oncology · doi:10.2217/fon-2019-0279 · Cited by 13
Sobrero, A. F., Pastorino, A., & Zalcberg, J. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01531 · Cited by 13
Farma, J. M., Olszanski, A. J., Messina, J. L., & Sondak, V. K. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16418-y · Cited by 14
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
Yue, M., Li, C., & Li, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111799 · Cited by 12
Gideonse, B. M., Birkeland, M., Vilstrup, M. H., Grupe, P., Naghavi‐Behzad, M., Ruhlmann, C. H. B., Gerke, O., & Hildebrandt, M. G. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01554-y · Cited by 12
Qin, Y., Zhang, T., Du, Z., Chen, S., Li, Y., Lv, Y., Du, X., Hu, Y., & Liu, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112385 · Cited by 15
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez, C. N., Sánchez‐Zuno, G. A., Osmani, L., Ibrahim, W., Galan, A., Bacchiocchi, A., Halaban, R., Kulkarni, R. P., Kang, I., Bucala, R., et al. (2024) · Oncotarget · doi:10.18632/oncotarget.28615 · Cited by 13
Ding, T., Chen, Q., Liu, H., Zhang, H., Sun, Y., Zhao, L., Gao, Y., & Wei, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37511 · Cited by 14
“Immunotherapy has arouse great excitement owing to its success in achieving long lasting responses in various tumors, including melanoma, lung cancer as well as CRC [10,11,41].”
BackgroundLocal administration of immunotherapy for patients with skin cancer: A systematic review
Janssen, J. C., van Dijk, B., Hoeijmakers, L. L., Grünhagen, D. J., Bramer, W. M., Verhoef, C. K., de Gruijl, T. D., Blank, C. U., & van der Veldt, A. A. M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102848 · Cited by 12
Self-citationLodde, G. C., Hassel, J. C., von Wasielewski, I., Meier, F. E., Mohr, P., Kähler, K. C., Hauschild, A., Glutsch, V., Stege, H. M., Berking, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02776 · Cited by 12
Self-citationPetrelli, F., Ghidini, A., Parati, M. C., Borgonovo, K., Rossitto, M., Ghilardi, M., Dognini, G. P., Petrò, D., Angeli, I., Lonati, V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186680 · Cited by 15
The Role of Neoadjuvant Therapy in Melanoma
Kelly, Z. R., Gorantla, V. C., & Davar, D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00944-5 · Cited by 13
Indini, A., Roila, F., Grossi, F., Massi, D., & Mandalà, M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00608-5 · Cited by 13
“In both trials, the survival improvement of adjuvant anti-PD1 was consistent across all patient subgroups, regardless of disease stage and BRAF mutational status [13, 15].”
BackgroundMa, E. Z., Hoegler, K. M., & Zhou, A. E. (2021) · Genes · doi:10.3390/genes12111751 · Cited by 15
Chen, S., Zhang, S., Yuan, Y., Wang, Z., Li, J., Li, T., Zuo, M., Feng, W., Chen, M., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016520 · Cited by 20
“Cancer immunotherapy, targeting enhancing natural defenses to attack malignant cells, has been confirmed to improve outcomes in multiple cancers (Eggermont et al., 2018; Gandhi et al., 2018; Choueiri et al., 2021; Cortes et al., 2022).”
BackgroundGroenen, P. J. T. A., van den Brand, M., Kroeze, L. I., Amir, A. L., & Hebeda, K. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1107171 · Cited by 12
“Immune-checkpoint inhibition therapies directed against inhibitory checkpoint molecules such as PD-1 and CTLA-4 have become standard-of-care for several types of tumors, such as stage III or IVmelanoma (70, 71), resectable lung cancer (72, 73), and colorectal cancer (74, 75).”
BackgroundLivingstone, A., Howard, K., Menzies, A. M., Long, G. V., Stockler, M. R., & Morton, R. L. (2023) · Patient · doi:10.1007/s40271-023-00635-w · Cited by 12
“The remaining four attributes were treated as continuous (linear) (i.e. the chance of recurrence at 3 years, fatal and permanent AEs, and OOP cost).”
BackgroundInfluentialSelf-citationLorini, L., Alberti, A., & Bossi, P. (2023) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1304a251 · Cited by 12
“One year duration is based on trials in other diseases, such as melanoma [22]; however, in the context of disease with high response to IT, a shorter period may be enough.”
BackgroundMahdiabadi, S., Momtazmanesh, S., Karimi, A., & Rezaei, N. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2278509 · Cited by 12
Gjorup, C. A., Woodford, R. G., Li, I., Carlino, M. S., Ch’ng, S., Chung, D. K. V., Hsiao, E., Lo, S., London, K., Long, G. V., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14526-9 · Cited by 12
Self-citationDeckers, E. A., Wevers, K. P., Kobold, A. C. M., Damude, S., Vrielink, O. M., van Ginkel, R. J., Been, L. B., van Leeuwen, B. L., Hoekstra, H. J., & Kruijff, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25682 · Cited by 12
Mohr, P., Kiecker, F., Soriano, V., Dereure, O., Mujika, K., Saïag, P., Utikal, J. S., Koneru, R., Robert, C., Cuadros, F., et al. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0015 · Cited by 12
Self-citationTian, Y., Zhang, Z., Yang, X., Li, D., Zhang, L., Li, Z., Zhang, S., Mao, Y., Jin, C., & Zhao, Y. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00261 · Cited by 12
“Similar incidence trend could also be seen when PD-1 inhibitor was compared with placebo or Ipilimumab (Figures 3C,F) (22, 23, 25).”
ResultKenyon-Smith, T., Kroon, H. M., Miura, J. T., Teras, J., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M., Farley, C. R., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.06.040 · Cited by 12
Ikeda, Y., Ono, M., Ohmori, G., Ameda, S., Yamada, M., Abe, T., Fujii, S., Fujita, M., & Maeda, M. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4008 · Cited by 12
Peil, J., Bock, F., Kiefer, F., Schmidt, R., Heindl, L. M., Cursiefen, C., & Schlereth, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031478 · Cited by 13
Darmon‐Novello, M., Adam, J., Lamant, L., Battistella, M., Ortonne, N., Balme, B., de la Fouchardière, A., Chaltiel, L., Gerard, É., Franchet, C., et al. (2022) · Histopathology · doi:10.1111/his.14651 · Cited by 12
“Immunotherapy is used to treat advanced-stage melanomas (metastatic melanomas); recently, adjuvant and neoadjuvant treatments have proven efficacious in the treatment of stage IIb and III melanoma.(1) Several studies have investigated factors that predict response to immunotherapy in patients with different types of c…”
BackgroundImmune checkpoint inhibitors – the revolutionary cancer immunotherapy comes with a cardiotoxic price
Achim, A., Liblik, K., & Gevaert, S. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.09.004 · Cited by 13
Zou, W., Luo, X., Gao, M., Chang, Y., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16054 · Cited by 18
“These PD-1/PD-L1 mAbs exert striking effects to prolong the survival of patients with advanced cancers including melanoma and non-small cell lung cancer (NSCLC), with a majority of patients even being completely cured (Eggermont et al., 2018; Huang et al., 2021; Tang et al., 2018).”
BackgroundUpdate on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
Swe, T., & Kim, K. B. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9913-y · Cited by 12
Hayes, A. J., Moskovic, E. C., O'Meara, K. W., Smith, H. G., Pope, R. J. E., Larkin, J., & Thomas, J. M. (2019) · British journal of surgery · doi:10.1002/bjs.11112 · Cited by 12
Self-citationFreeman, M. L., Betts, K. A., Jiang, S., Du, E. X., Gupte-Singh, K., Lu, Y., Rao, S. A., & Shoushtari, A. N. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01060-y · Cited by 12
“On the basis of an approximate assessment, the first-year drug acquisition cost of nivolumab was similar to that of pembrolizumab ($169,898 based on approved doses) in resected melanoma [29, 30].”
BackgroundTapia, C., Aung, P. P., Roy‐Chowdhuri, S., Xu, M., Ouyang, F., Alshawa, A., Hajjar, J., Singh, G., Yang, V. W., Castillo, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000665 · Cited by 12
Mueller, K. L., Theoret, M. R., Lemery, S. J., Amiri‐Kordestani, L., Ariyan, C. E., Atkins, M. B., Berry, D. A., Blank, C. U., DeMichele, A. M., Forde, P. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3285 · Cited by 12
“Similarly, in all comers, the PD-1 blocking mAbs pembrolizumab and nivolumab each increased 1-year RFS to >70%, compared with 50%–60% in patients receiving placebo control or singleagent ipilimumab (7, 8).”
BackgroundSelf-citationEighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
Brancaccio, G., Napolitano, S., Troiani, T., Franco, R., Iovino, F., Reginelli, A., Ciardiello, F., & Argenziano, G. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17145 · Cited by 12
Plüss, L., Peissert, F., Elsayed, A., Rotta, G., Römer, J., Plaza, S. D., Villa, A., Puca, E., Luca, R. D., Oxenius, A., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2217964 · Cited by 11
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ
Newey, A., Yu, L., Barber, L. J., Choudhary, J. S., Bassani‐Sternberg, M., & Gerlinger, M. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0121 · Cited by 11
Lu, Q., Zhou, W., Fan, L., Ding, T., Wang, W., & Zhang, X. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001565 · Cited by 11
Gawaz, A., Wolff, I., Nanz, L., Flatz, L., & Forschner, A. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03750-1 · Cited by 12
“Efficacy and safety of ICI have been examined thoroughly in several studies including patients aged 65 years or older, but real-world data focusing on patients ≥ 75 years is missing [3, 7–9].”
BackgroundVargas, G. M., Farooq, M. S., & Karakousis, G. C. (2024) · Cancers · doi:10.3390/cancers16152690 · Cited by 13
Weber, J. S., Vecchio, M. D., Mandalà, M., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J., Chiarion‐Sileni, V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01448 · Cited by 11
Self-citationChen, J., Tarantino, G., Severgnini, M., Bagińska, J., Giobbie‐Hurder, A., Weirather, J. L., Manos, M. P., Russell, J. D., Pfaff, K. L., Rodig, S. J., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2432723 · Cited by 13
Melanoma neoadjuvant treatment: review and update of recent trials
Ferrari, M., Facchini, B. A., Ascierto, P. A., & Sparano, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2474182 · Cited by 12
Self-citationCirculating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study
Rhodin, K. E., O’Connor, M. H., Therien, A. D., Hollander, S., Geron, V., Nair, U., Rakestraw, E., Salama, A. K. S., Shah, R., Tyler, D. S., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17194-z · Cited by 13
Lens, M. B., & Schachter, J. (2025) · Cancers · doi:10.3390/cancers17111835 · Cited by 12
“In this study, 1011 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB, or IIIC melanoma were assigned to adjuvant pembrolizumab therapy or a placebo [56].”
Teng, M., Zhang, L., Fan, Y., Fu, M., & Li, Z. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114238 · Cited by 11
Roy, S., Banerjee, D., Banerjee, A., & Choudhury, L. (2025) · Biologia Futura · doi:10.1007/s42977-025-00291-1 · Cited by 13
“It has been demonstrated that these medications slow the growth of specific solid tumor types like prostate cancer, ovarian cancer, non small cell lung cancer and stage III melanoma (Cha et al. 2020; Nishio et al. 2019; Varga et al. 2019; Gandhi et al. 2018; Eggermont et al. 2018).”
Carlino, M. S., Khattak, M. A., Meniawy, T. M., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M. A., Long, G. V., Sullivan, R. J., Faries, M. B., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00008 · Cited by 13
Self-citationToxicities from immunotherapy: From clinical trials to real-world clinical practice
Riveiro‐Barciela, M., Araguás, E. T., Martínez‐Valle, F., Roca-Herrera, M., Zamora, E., Barreira‐Díaz, A., & Muñoz‐Couselo, E. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.06.057 · Cited by 11
Wang, Y., Lian, B., Si, L., Mao, L., Chi, Z., Sheng, X., Kong, Y., Wang, X., Bai, X. L., Yan, X., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.008 · Cited by 11
Selection of a PD ‐1 blocking antibody from a novel fully human phage display library
Peissert, F., Plüss, L., Giudice, A. M., Ongaro, T., Villa, A., Elsayed, A., Nadal, L., Plaza, S. D., Scietti, L., Puca, E., et al. (2022) · Protein Science · doi:10.1002/pro.4486 · Cited by 11
Immune checkpoint inhibitor-related thyroid dysfunction
Illouz, F., Briet, C., & Rodien, P. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.005 · Cited by 11
Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
Veld, E. A. H. I. ’., Boere, T., Zuur, C. L., Wouters, M. W. J. M., van Akkooi, A. C. J., Haanen, J. B. A. G., Crijns, M. B., Smith, M. J. F., Mooyaart, A. L., Wakkee, M., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13306-9 · Cited by 13
“Number of positive lymph nodes (median, range) 2 (1-32)”
BackgroundPembrolizumab for the adjuvant treatment of IIB or IIC melanoma
Rutkowski, P. L., & Czarnecka, A. M. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2247565 · Cited by 11
“Pembrolizumab has also been approved as adjuvant treat-ment for resected stage III melanoma on the basis of the results of the European Organization for Research and Treatment of Cancer (EORTC) 1325 ( KEYNOTE-054 ) clinical trial (NCT02362594) [10].”
BackgroundMethodSelf-citationImmune Checkpoint Inhibitor-Induced Liver Injury
Gudd, C. L. C., Sheth, R., Thursz, M. R., Triantafyllou, E., & Possamai, L. A. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1776761 · Cited by 12
Zhao, J., Guo, Y., Feng, T., Rong, D., Kong, X., Huang, T., López‐López, V., Yarmohammadi, H., Sakamoto, Y., Zhu, D., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-590 · Cited by 13
Actualités dans le mélanome cutané
Longvert, C., & Saïag, P. (2018) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.11.005 · Cited by 18
Precision Medicine in the Treatment of Melanoma
Aderhold, K., Wilson, M. A., Berger, A. C., Levi, S. T., & Bennett, J. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.001 · Cited by 11
Khunger, A., Piazza, E., Warren, S. E., Smith, T. H., Ren, X., White, A. M., Elliott, N., Cesano, A., Beechem, J., Kirkwood, J. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245287 · Cited by 11
Wurcel, V., Scherrer, E., Aguiar‐Ibáñez, R., Altuna, J. I., Carabajal, F., Jain, S., & Baluni, G. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00142-8 · Cited by 11
“The overall target population for the economic evaluation is aligned with the patient population enrolled in the KEYNOTE-054 trial and the Argentinian label: melanoma patients with lymph node involvement who have undergone complete resection [16, 17].”
BackgroundDrug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
Cherri, S., Noventa, S., Fanelli, M., Calandra, G., Prochilo, T., Bnà, C., Savelli, G., & Zaniboni, A. (2021) · Cancers · doi:10.3390/cancers13051052 · Cited by 12
Adda, L., Batteux, B., Saidak, Z., Poulet, C., Arnault, J., Chauffert, B., & Séjourné, A. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105168 · Cited by 13
Grubb, A. F., & Hankollari, E. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02690-z · Cited by 11
Wolfe, A. R., Chablani, P. V., Siedow, M. R., Miller, E. D., Walston, S., Kendra, K. L., Wuthrick, E. J., & Williams, T. M. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01903-5 · Cited by 11
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.